Thymosin β4 vs TB-500
An endogenous actin-sequestering peptide involved in wound healing. A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Thymosin β4 Tβ4 | TB-500 | |
|---|---|---|
| Also known as | — | — |
| Type | Endogenous | Research |
| Evidence | Established | Preclinical |
| Family | Repair & regenerative | Repair & regenerative |
| Class | Actin-binding peptide (43 aa) | N-acetylated thymosin β4 fragment (7 aa; Ac-LKKTETQ) |
| Receptor / target | No classical receptor; sequesters monomeric (G-)actin | No established receptor; fragment effects cannot be assumed equivalent to thymosin β4 |
| Molecular weight | ~4,963.4 Da | — |
| Half-life | Poorly characterized in humans | Poorly characterized in humans |
| Based on | Native hormone | Thymosin β4 |
Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Thymosin β4 and TB-500?
- Thymosin β4 is an endogenous hormone; TB-500 is a research peptide based on Thymosin β4. Thymosin β4 signals at No classical receptor; sequesters monomeric (G-)actin; TB-500 signals at No established receptor; fragment effects cannot be assumed equivalent to thymosin β4.
- How do the half-lives of Tβ4 and TB-500 compare?
- The reported circulating half-life of Thymosin β4 is Poorly characterized in humans; TB-500 is Poorly characterized in humans. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? TB-500 vs Thymosin β4. Or open the interactive comparison tool to add more molecules.